Eric H. Zanelli

Biography

Eric co-founded Déclion Pharmaceuticals in 2011. Eric has more than twenty years of experience in leading research and development organizations in the life sciences and academia. Eric is a world expert in amino acid copolymers and declensional peptides and is the inventor of the DEEP platform. Prior to Déclion, Eric served as the Vice President, Research and Development at Peptimmune, Inc., where he developed PI-2301, a random sequence amino acid copolymer for the treatment of multiple sclerosis. PI-2301 is entering phase 2 clinical trials and was acquired in 2011 by Merck-Serono. Eric has also held positions as a Senior Scientist at Praecis Pharmaceuticals, Project Leader at Cardion Pharmaceuticals, Inc. and as an Assistant Professor at Leiden University Medical Center in the Netherlands. Eric is from Marseille, France, and received his doctorate in Immunology from University of Luminy, and completed post-doctoral training at the Mayo Clinic in Minnesota. Eric is also an avid tennis player 

Research Interest

Déclion is a privately held biotechnology company focused on the development of declensional peptides